Effect of nicotine on advanced glycation end product-induced immune response in human monocytes

J Pharmacol Exp Ther. 2010 Mar;332(3):1013-21. doi: 10.1124/jpet.109.160861. Epub 2009 Dec 2.

Abstract

The up-regulation of adhesion molecule expressions on monocytes enhances cell-to-cell interactions with T cells, leading to cytokine production. Advanced glycation end products (AGEs) are modifications of proteins/lipids that become nonenzymatically glycated after contact with aldose sugars. Among various subtypes of AGEs, glyceraldehyde-derived AGE (AGE-2) and glycolaldehyde-derived AGE (AGE-3) induce the expressions of intercellular adhesion molecule-1, B7.1, B7.2, and CD40 on monocytes, the production of interferon-gamma and tumor necrosis factor-alpha, and the lymphocyte proliferation in human peripheral blood mononuclear cells. Nicotine is reported to inhibit the activation of monocytes via nicotinic acetylcholine receptor alpha7 subunit (alpha7-nAChR). In the present study, we found that nicotine inhibited the actions of AGE-2 and AGE-3. A nonselective and selective alpha7-nAChR antagonist, mecamylamine and alpha-bungarotoxin, reversed the inhibitory effects of nicotine, suggesting the involvement of alpha7-nAChR stimulation. Nicotine induced the expression of cyclooxygenase-2, prostaglandin E(2) (PGE(2)), and cAMP in the presence and absence of AGE-2 and AGE-3. PGE(2) is known to activate the EP(2)/EP(4) receptor, increasing the cAMP level and protein kinase A (PKA) activity. The actions of nicotine were reversed in part by an EP(2)-receptor antagonist, AH6809, an EP(4)-receptor antagonist, AH23848, and a PKA inhibitor, N-[2-(p-bromocinnamyl-amino)ethyl]-5-isoquinolinesulfonamide dihydrochloride (H89). These results indicate that the mechanism of action of nicotine may be partially via endogenous PGE(2) production.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • B7-2 Antigen / biosynthesis
  • CD40 Antigens / biosynthesis
  • Cell Proliferation
  • Cyclic AMP / biosynthesis
  • Cyclic AMP-Dependent Protein Kinases / physiology
  • Cyclooxygenase 2 / biosynthesis
  • Dinoprostone / biosynthesis
  • Glycation End Products, Advanced / immunology*
  • Glycation End Products, Advanced / metabolism
  • Humans
  • In Vitro Techniques
  • Intercellular Adhesion Molecule-1 / biosynthesis
  • Interferon-gamma / biosynthesis
  • Leukocytes, Mononuclear / cytology
  • Leukocytes, Mononuclear / drug effects
  • Leukocytes, Mononuclear / metabolism
  • Monocytes / drug effects*
  • Monocytes / immunology
  • Monocytes / metabolism
  • Nicotine / pharmacology*
  • Nicotinic Agonists / pharmacology*
  • Nicotinic Antagonists / pharmacology
  • Receptors, Nicotinic / physiology
  • Receptors, Prostaglandin E / physiology
  • Receptors, Prostaglandin E, EP2 Subtype
  • Receptors, Prostaglandin E, EP4 Subtype
  • Tumor Necrosis Factor-alpha / biosynthesis
  • alpha7 Nicotinic Acetylcholine Receptor

Substances

  • B7-2 Antigen
  • CD40 Antigens
  • CD86 protein, human
  • Chrna7 protein, human
  • Glycation End Products, Advanced
  • Nicotinic Agonists
  • Nicotinic Antagonists
  • PTGER2 protein, human
  • PTGER4 protein, human
  • Receptors, Nicotinic
  • Receptors, Prostaglandin E
  • Receptors, Prostaglandin E, EP2 Subtype
  • Receptors, Prostaglandin E, EP4 Subtype
  • Tumor Necrosis Factor-alpha
  • alpha7 Nicotinic Acetylcholine Receptor
  • Intercellular Adhesion Molecule-1
  • Nicotine
  • Interferon-gamma
  • Cyclic AMP
  • Cyclooxygenase 2
  • Cyclic AMP-Dependent Protein Kinases
  • Dinoprostone